IL1B and macrophage activation syndrome: Although most patients received at least part of their steroid treatment intravenously, 28% (8 of 29) of episodes were managed with oral steroids, besides the continuation of their IL‐1–targeted therapy, often in temporarily higher dosages due to MAS.